Cargando…

Effectiveness of Safinamide over Mood in Parkinson’s Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR

INTRODUCTION: Mood disorders are frequent in Parkinson’s disease (PD) and a favorable effect of safinamide on mood has been observed. We aimed to analyze the effectiveness of safinamide on mood as a secondary objective from the SAFINONMOTOR (an open-label study of the effectiveness of SAFInamide on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Labandeira, Carmen M., Alonso Losada, Maria G., Yáñez Baña, Rosa, Cimas Hernando, Maria I., Cabo López, Iria, Paz González, Jose M., Gonzalez Palmás, Maria J., Martínez Miró, Cristina, Santos García, Diego
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8440147/ https://www.ncbi.nlm.nih.gov/pubmed/34523075 http://dx.doi.org/10.1007/s12325-021-01873-w

Ejemplares similares

Safinamide improves sleep and daytime sleepiness in Parkinson’s disease: results from the SAFINONMOTOR study
por: Santos García, Diego, et al.
Publicado: (2021)

Pain Improvement in Parkinson’s Disease Patients Treated with Safinamide: Results from the SAFINONMOTOR Study
por: Santos García, Diego, et al.
Publicado: (2021)

Safinamide Improves Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study
por: Santos García, Diego, et al.
Publicado: (2021)

Vortioxetine Improves Depressive Symptoms and Cognition in Parkinson’s Disease Patients with Major Depression: An Open-Label Prospective Study
por: Santos García, Diego, et al.
Publicado: (2022)

Long-Term Effects of Safinamide on Mood Fluctuations in Parkinson’s Disease
por: Cattaneo, Carlo, et al.
Publicado: (2017)

SURINPARK: Safinamide for Urinary Symptoms in Parkinson’s Disease
por: Gómez-López, Ana, et al.
Publicado: (2021)

The effects of safinamide on dysphagia in Parkinson’s disease
por: Hirano, Makito, et al.
Publicado: (2023)

Impact of Safinamide on Patient-Reported Outcomes in Parkinson’s Disease
por: Espinoza-Vinces, Christian, et al.
Publicado: (2023)

Safinamide: an add-on treatment for managing Parkinson’s disease
por: Müller, Thomas
Publicado: (2018)

Investigational agents in the treatment of Parkinson’s disease: focus on safinamide
por: Malek, Naveed M, et al.
Publicado: (2012)

Adjuvant therapies for Parkinson’s disease: critical evaluation of safinamide
por: Stocchi, Fabrizio, et al.
Publicado: (2016)

Emerging approaches in Parkinson’s disease – adjunctive role of safinamide
por: Müller, Thomas
Publicado: (2016)

Effects of safinamide on pain in patients with fluctuating Parkinson's disease
por: Grigoriou, Sotirios, et al.
Publicado: (2021)

The Current Evidence for the Use of Safinamide for the Treatment of Parkinson's Disease
por: Abbruzzese, Giovanni, et al.
Publicado: (2021)

A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice
por: Pagonabarraga, Javier, et al.
Publicado: (2020)

Population pharmacokinetic and pharmacodynamic analyses of safinamide in subjects with Parkinson's disease
por: Loprete, Luca, et al.
Publicado: (2016)

Long-term Efficacy of Safinamide on Parkinson’s Disease Chronic Pain
por: Cattaneo, Carlo, et al.
Publicado: (2018)

The Efficacy of Safinamide in the Management of Parkinson's Disease: A Systematic Review
por: Sharaf, Joudi, et al.
Publicado: (2022)

Fatigue in fluctuating Parkinson’s disease patients: possible impact of safinamide
por: Pauletti, Caterina, et al.
Publicado: (2023)

Changes in Principal Caregiver Mood Affects the Mood of the Parkinson’s Disease Patient: The Vicious Cycle of Illness
por: Santos-García, Diego, et al.
Publicado: (2023)

Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations
por: Borgohain, Rupam, et al.
Publicado: (2014)

Safinamide in the treatment pathway of Parkinson’s Disease: a European Delphi Consensus
por: Stocchi, Fabrizio, et al.
Publicado: (2022)

Efficacy of Safinamide and Gender Differences During Routine Clinical Practice
por: Pellecchia, Maria T., et al.
Publicado: (2021)

Effectiveness and safety of safinamide in routine clinical practice in a Belgian Parkinson’s disease population: an open-label, levodopa add-on study
por: Bergmans, Bruno, et al.
Publicado: (2022)

Effects of Safinamide on Pain in Fluctuating Parkinson’s Disease Patients: A Post-Hoc Analysis
por: Cattaneo, Carlo, et al.
Publicado: (2017)

Safinamide in Clinical Practice: A Spanish Multicenter Cohort Study
por: Martí-Andrés, Gloria, et al.
Publicado: (2019)

Impact of SAfinamide on Depressive Symptoms in Parkinson’s Disease Patients (SADness-PD Study): A Multicenter Retrospective Study
por: Peña, Esteban, et al.
Publicado: (2021)

Safinamide in the management of patients with Parkinson’s disease not stabilized on levodopa: a review of the current clinical evidence
por: Bette, Sagari, et al.
Publicado: (2018)

Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson’s Disease Patients
por: Cattaneo, Carlo, et al.
Publicado: (2020)

Overall Efficacy and Safety of Safinamide in Parkinson’s Disease: A Systematic Review and a Meta-analysis
por: Giossi, Riccardo, et al.
Publicado: (2021)

A systematic review and meta-analysis of safety and efficacy of safinamide for motor fluctuations in patients with Parkinson's disease
por: Abdelalem Aziz Ahmed, Mohamed
Publicado: (2019)

A Randomized Clinical Trial to Evaluate the Effects of Safinamide on Apathetic Non-demented Patients With Parkinson's Disease
por: Kulisevsky, Jaime, et al.
Publicado: (2022)

Collective Expert Perspectives on the Use of Safinamide as Adjunctive Therapy for Parkinson's Disease: Online-Based Delphi Survey
por: Takeda, Atsushi, et al.
Publicado: (2022)

The effects of safinamide according to gender in Chinese parkinsonian patients
por: Pellecchia, M. T., et al.
Publicado: (2023)

Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson’s Disease: A Post-Hoc Analysis
por: Cattaneo, Carlo, et al.
Publicado: (2015)

Switching from Rasagiline to Safinamide as an Add-On Therapy Regimen in Patients with Levodopa: A Literature Review
por: Sanchez Alonso, Pilar, et al.
Publicado: (2023)

Erratum: Pagonabarraga, J.; et al. A Spanish Consensus on the Use of Safinamide for Parkinson’s Disease in Clinical Practice. Brain Sci. 2020, 10, 176
por: Pagonabarraga, Javier, et al.
Publicado: (2020)

Levodopa Equivalent Dose of Safinamide: A Multicenter, Longitudinal, Case–Control Study
por: Cilia, Roberto, et al.
Publicado: (2023)

Effects of safinamide on non-motor, cognitive, and behavioral symptoms in fluctuating Parkinson’s disease patients: a prospective longitudinal study
por: De Micco, Rosa, et al.
Publicado: (2021)

Non-motor symptoms burden in motor-fluctuating patients with Parkinson’s disease may be alleviated by safinamide: the VALE-SAFI study
por: De Masi, Claudia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_s3363ho249ak9qje9k4jtujcff